Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Bo Jia et al.|Journal of Hematology & Oncology|2017Cited by 256
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Kaiyang Ding et al.|The Lancet Oncology|2023Cited by 55
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Xin Zhang, Yongping Song et al.|Journal of Hematology & Oncology|2020Cited by 50
Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy‐based virtual screening and machine learning evaluationXi Chen, Tao Lei, Jingyi Zhao et al.|Archiv der Pharmazie|2024Cited by 2